Human babies aren’t that special after all

human babies

Human babies take a long time to start walking

The onset of walking for human babies is thought to represent a critical milestone in development of the nervous system, when neuronal systems mature enough to coordinate the complex movements of multiple limbs and prevent the animal from falling over.

How long it takes for human babies to start walking is one area that scientists originally thought that humans differ from other mammals.

A human baby only starts to walk on shaky legs around a year after birth, but a foal can get up almost immediately and rodents like mice only require a few hours to start moving around. In a new study published in PNAS, a group from Lund University in Sweden has found why this difference exists – and surprisingly, it’s not because humans are uniquely different.

Most mammals start walking around the same developmental time!
They showed that human babies actually start walking at the same brain developmental stage as most other mammals that walk. If you look at progression of brain development after conception, and not birth, humans start walking at the same relative point in time.

This shows that the neural mechanisms that underlie the ability to walk are very similar across animals and the neural building blocks of human brains come together in a similar manner as even lower mammals that diverged in evolution many millions of years ago.

Analyzing brain development data from other animals allowed them to predict quite accurately when humans would start to walk. Though humans may be different in many ways, motor development of the brain is not one of them.

These findings shed new light on how developmental paths in early life could have been conserved evolutionarily from lower organisms all the way up to humans, and they lead to better understanding of the developmental clock and what events occur at what stage of development, which may have relevance for treating developmental disorders in the future.

“Human babies” Photo by Photostock.

Your appetite might be linked to risk of Alzheimer’s disease

Alzheimer's disease

Alzheimer’s disease – Appetite might be linked to risk of Alzheimer’s

The hormone leptin controls your appetite
Leptin is a potent and important appetite-regulating hormone – if you’ve just polished off a couple plates of food at a buffet, your blood leptin levels will rise and signal to your brain that you’re full.

The picture to the right shows an obese mouse that is missing the leptin gene and thus doesn’t produce leptin in its body. When it starts eating, it doesn’t stop and becomes obese.

The same thing happens in a small population of humans who are missing the leptin gene. They can’t control their appetite and get fat. But as always in biology, the story is more complicated. Some obese people have exactly the opposite effect – higher leptin levels than normal.

This might be because they have a genetic defect that makes them resistant to the effects of the hormone – when their bodies detect that the existing leptin in the bloodstream isn’t working, more leptin is pumped out, leading to higher levels.

Higher leptin = less risk of Alzheimer’s disease
A group of researchers based in Boston University have just finished an epic 12-year study of over 750 elderly people, where they tracked leptin levels and brain function (with brain scans). In short, they found that people with overall higher leptin levels at the start of the study ended up with less Alzheimer’s disease and healthier brains.

This is exciting because it would be extremely powerful to find a way to predict whether somebody is going to get Alzheimer’s disease later in their life, allowing early intervention and treatment – this study shows that leptin might be a useful predictive biomarker.

Now you might be thinking, if people with lower leptin levels get more Alzheimer’s disease, why don’t we give them some more leptin? Great minds think alike, because that’s exactly what Dr. J. Wesson Ashford and the Stanford/VA Alzheimer’s Center received $3M from the NIH (National Institute of  Health) to look into.

Of course, any clinical application of this leptin / Alzheimer’s disease work is still many years away, but it’s good to see progress being made in understanding risk factors for Alzheimer’s disease.